Sofiva Genomics is invited to participate Investor
Conference held by GrandFortune Securities
Date of events
2022/04/13
To which item it meets
paragraph 12
Statement
1.Date of institutional investor conference:2022/04/13
2.Time of institutional investor conference:2:00 p.m.(Taiwan Time)
3.Location of institutional investor conference:
Online investor conference
4.Outline of institutional investor conference:
Financial and business related information
5.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Sofiva Genomics Co. Ltd. published this content on 12 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 April 2022 06:30:08 UTC.
Sofiva Genomics Co Ltd is a Taiwan-based company mainly engaged in provision of deoxyribonucleic acid (DNA) testing services. The Company's DNA testing services mainly contain reproductive medicine testing, pregnant women testing, newborn testing, rare disease genetic testing, personalized genetic testing, cancer genetic testing, and genetic counseling services. Reproductive Medicine testing is pre-implantation genetic diagnosis for embryos. Pregnant women testing services predict the occurrence of preeclampsia and provide prenatal diagnosis. Neonatal testing services provide neonatal hearing loss genetic test, respiratory distress syndrome test, congenital cytomegalovirus infection test service. Personalized genetic testing services includes human papilloma virus screening, paternity testing, telomere testing, chronic disease and cardiovascular disease and other genetic research. Cancer genetic testing services is applied to cancer patients.
SOFIVA GENOMICS CO.,LTD. 
